Santhera Pharmaceuticals share#snapshot#suffix
| 13,86CHF | 0,72CHF | 5,48% |
WKN DE: A3EJMQ / ISIN: CH1276028821
Santhera Pharmaceuticals share#search#balancesheet/share#balance#headline#income_statement
share#balance#profitpershare- Santhera Pharmaceuticals
| -3,7 24 | 5,2 23 | -11,7 22 | -16,2 21 | -50,8 20 | -17,3 19 | -78,6 18 |
share#balance#salespershare- Santhera Pharmaceuticals
| 3,4 24 | 9,5 23 | 1,2 22 | -0,5 21 | 11,3 20 | 68,6 19 | 45,9 18 |
share#balance#p_e_ratio- Santhera Pharmaceuticals
| 1,9 23 |
Santhera Pharmaceuticals AG: share#balance#headline#theshare (in CHF)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | -3,69 | 5,18 | -11,70 | -16,20 | -50,80 | -17,30 | -78,60 |
| Gewinn je Aktie (unverwässert) | -3,69 | 5,18 | -11,67 | -16,25 | -50,81 | -17,26 | -78,63 |
| Gewinn je Aktie (verwässert) | -3,69 | 5,02 | -11,67 | -16,25 | -50,81 | -17,26 | -78,63 |
| Dividende je Aktie | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Veränderung Dividende je Aktie in % | - | - | - | - | - | - | - |
| share#balance#cell#dividend_payment | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Santhera Pharmaceuticals AG: share#balance#business_ratio (in CHF)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| share#balance#cell#sales_share | 3,44 | 9,47 | 1,23 | -0,47 | 11,27 | 68,58 | 45,94 |
| KGV (Jahresendkurs, Gewinn unverwässert) | - | 1,89 | - | - | - | - | - |
| KGV (Jahresendkurs, Gewinn verwässert) | - | 1,96 | - | - | - | - | - |
| share#balance#cell#dividend_ratio | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| share#balance#cell#equity_ratio | 18,16 | 54,68 | -68,55 | 1,46 | -7,16 | 18,47 | 25,23 |
| share#balance#cell#debt_ratio | 81,84 | 45,32 | 168,55 | 98,54 | 107,16 | 81,53 | 74,77 |
Santhera Pharmaceuticals AG: share#balance#headline#income_statement (in Mio. CHF)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| share#balance#cell#sales | 39,12 | 103,41 | 7,47 | -1,60 | 15,01 | 75,38 | 31,66 |
| share#balance#cell#sales_change | -62,17 | 1 283,84 | - | - | -80,09 | 138,10 | 37,98 |
| share#balance#cell#sales_gross_profit | 22,91 | 99,54 | 3,27 | -6,05 | 0,48 | 68,19 | 26,25 |
| share#balance#cell#sales_gross_profit_change | -76,98 | 2 941,37 | - | - | -99,30 | 159,77 | 41,93 |
| share#balance#cell#operating_income | -33,38 | 50,54 | -45,87 | -57,13 | -53,57 | -6,60 | -51,53 |
| share#balance#cell#operating_income_change | - | - | 19,72 | -6,66 | -711,84 | 87,20 | -1,73 |
| share#balance#cell#income_before_tax | -41,66 | 54,82 | -70,62 | -54,72 | -67,46 | -18,39 | -53,86 |
| share#balance#cell#income_before_tax_change | - | - | -29,06 | 18,88 | -266,73 | 65,85 | -5,05 |
| share#balance#cell#income_after_tax | -41,97 | 54,78 | -71,08 | -55,53 | -67,66 | -18,97 | -54,19 |
| share#balance#cell#income_after_tax_change | - | - | -28,00 | 17,93 | -256,61 | 64,99 | -5,15 |
Santhera Pharmaceuticals AG: share#balance#headline#balance (in Mio. CHF)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 125 | 50 | 107 | 90 | 95 | 94 | 82 |
| Langzeit Gesamtverbindlichk. je Aktie | 6,15 | 0,47 | 8,80 | 11,50 | 36,39 | 62,86 | 59,14 |
| share#balance#cell#total_equity | 28 | 60 | -44 | 1 | -6 | 21 | 28 |
| share#balance#cell#total_equity_change | -53,79 | - | -3 389,61 | - | -129,91 | -23,65 | -13,72 |
| share#balance#cell#total_liabilities_and_equity | 152 | 110 | 64 | 91 | 89 | 115 | 110 |
| share#balance#cell#total_liabilities_and_equity_change | 39,09 | 72,03 | -30,06 | 2,74 | -22,92 | 4,31 | 0,47 |
Santhera Pharmaceuticals AG: share#balance#headline#other_data (in CHF)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | -3,69 | 5,18 | -11,67 | -16,25 | -50,81 | -17,26 | -78,63 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -171,18 | - | 28,21 | 68,02 | -194,36 | 78,05 | 4,35 |
| Gewinn je Aktie (verwässert) | -3,69 | 5,02 | -11,67 | -16,25 | -50,81 | -17,26 | -78,63 |
| Veränderung Gewinn je Aktie (verwässert) in % | -173,50 | - | 28,21 | 68,02 | -194,36 | 78,05 | 4,35 |
| share#balance#cell#employees | 78 | 44 | 45 | 43 | 91 | 117 | 119 |
| share#balance#cell#employees_change | 75,22 | -2,18 | 6,51 | -52,75 | -22,22 | -1,68 | 6,25 |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.